Growth in children with chronic kidney disease: role of nutrition, growth hormone, dialysis, and steroids.

What It Covers

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a review.

Children with chronic kidney disease (CKD) have impaired growth that leads to short stature in adulthood.

The problem persists even with successful transplantation and steroid withdrawal protocols.

The aim of this review is to provide an overview of the pressing issues related to growth failure in children with CKD both before and after transplantation.

Why It Was Studied

The causes of growth failure in the setting of CKD are multifactorial.

Attention to all the details by optimizing nutritional, bone and mineral metabolism, correcting metabolic acidosis and anemia, achieving excellent blood pressure control, reversing cardiovascular complications such as left ventricular hypertrophy, and minimizing the use of corticosteroids is the current standard of care.

Who the Included Studies Covered

By PubMed's age tags, the people studied were children.

What Was Measured

The subject headings attached to it are Body Height, Growth Disorders, Human Growth Hormone, Kidney Transplantation, Nutritional Support, Practice Guidelines as Topic and Quality of Life.

What This Means in Plain Language

This is a review of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Current opinion in pediatrics), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.